



Post Authorisation Assessments

For details of post authorisation assessments prior to 1st January 2021,
please refer to the [EMA](#) website.

Zolvix 25 mg/ml Oral Solution for Sheep

Vm 52127/5029

18 December 2025	Addition of a site responsible for microbiological testing for a finished product.
12 June 2025	Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV).
20 December 2024	Change in batch size of intermediates used in the manufacturing process of the active substance. Editorial changes to part 2 of the dossier if inclusion in an upcoming procedure concerning part 2 is not possible. Minor changes in the manufacturing process of an active substance.
01 December 2024	Change of specifications of a former non-EU Pharmacopoeial excipient to fully comply with the Ph. Eur.
27 October 2024	Change in the manufacturing process of the finished product, other changes under this code level.
29 August 2023	One-off alignment of the product information with version 9.0* of the QRD templates.
28 July 2023	Extension in the re-test period of the active substance where no Ph. Eur. Certificate of Suitability covering the retest period is part of the approved dossier.
10 May 2023	Change in manufacturer responsible for batch control of the active substance.
18 April 2023	Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer.